Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group.

@article{Zwerdling2006PhaseII,
  title={Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group.},
  author={Ted Zwerdling and Mark D. Krailo and Philip Monteleone and Rebecca Byrd and Judith K. Sato and Rose Dunaway and Nita Seibel and Zhengjia Chen and John A. Strain and Gregory Reaman},
  journal={Cancer},
  year={2006},
  volume={106 8},
  pages={1821-8}
}
BACKGROUND Docetaxel, which is an antitubulin agent, has demonstrable activity against murine and human tumors. The current study was designed to determine response rates to docetaxel in various strata of recurrent solid tumors of childhood and to assess toxicity in a group of patients who were assigned to receive it. METHODS Docetaxel was given at a dose of 125 mg/m2 once every 21 days as a 1-hour intravenous infusion for a maximum of 12 courses. From January 1997 to November 2001, 109 male… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…